2 Burst results for "Venice Shore"
AP News Radio
Airplane crash in Gulf of Mexico leaves 2 dead, 1 missing
"Two people are confirmed dead and authorities are searching for a third person after a private plane crashed into the Gulf of Mexico off the Florida coast. The plane crash happened Saturday night, but a search for the rented single engine piper Cherokee didn't begin until around 10 a.m. Sunday, when the plane had not returned to the airport where it had left in St. Petersburg, Florida, a spokesperson in Venice, Florida says recreational boaters found the body of a woman floating about two and a half miles west of the Venice shore, and divers from the Sarasota county sheriff's office located the plains wreckage, about a third of a mile off shore, directly west of the Venice airport, the body of a girl was found in the plains passenger area, and rescuers are searching for a third person, believed to be a man who was either the pilot or a passenger. I'm Donna water
Marketplace Morning Report with David Brancaccio
"venice shore" Discussed on Marketplace Morning Report with David Brancaccio
"This marketplace podcast is supported by masterworks in the past six months investors. Lost one hundred sixty seven billion dollars on meam stocks. That's why sophisticated investors are buying art. And it's no surprise. Why contemporary art prices rose fourteen percent per year from nineteen ninety five through two thousand twenty outperforming stocks real estate and gold over the same period masterworks dot. Io lets you. Invest in multimillion dollar works by artists like bank and warhol at a fraction of the entry cost morning report. Listeners can skip their wait. Lists by going to masterworks dot. Io slash morning today see disclosures at masterworks dot io slash disclaimer. Bacteria have been developing resistance to antibiotics for basically as long as we've had antibiotics since the mid nineteen forties. Humans are losing ground and not simply because of the evolutionary tenacity of bacteria but also because of economics markets are not developing new antibiotics fast. Enough orense maryn mckenna journalist and senior fellow at the center for the study human health at emory university. She wrote about this for the mit technology review and joins us. Now good morning. thanks for having me. So we are in this race with deadly organisms. And yet you have pointed out all the big players who would make or develop new. Antibiotics left the business nearly twenty years ago. Why if you think back to the last time you took an antibiotic or a member of your family did. You probably didn't take that drug for very long. It probably didn't cost all that much money and when you were done that infection that you were taking the antibiotics four should have gone away. All of those conditions are really different than most of the other drugs that pharmaceutical companies make and want to make money for the cost of making a drug. Don't actually vary is a category of drugs that you're making but the amount of revenue that you get back at the far end of that is much greater if you're making a cancer drug immunology drug a drug for cardiovascular disease than if you're making an antibiotic you also talk about something called the valley of death problem when it comes to drug development specifically for antibiotics. Can you explain that for us with those big companies with multiple income streams. Having left the landscape it falls too small biotechs who have no other sources of income except friends and family or maybe vc investors to fund all of those phases of trials. Some of which can be very large and so it's possible for them to run out of money before they get all the way to the end of the process to the fda and get their drug approved. There's kind of a second valley of death which is after approval but before a drug gets to profitability in the past couple of years a number of the small biotechs that were making new drugs. Have gone bankrupt put themselves up for auction. In in various ways left the sector and many of them did it after their drug had reached approval so the economic landscape is super tricky. People have pointed out in the past that the economics of developing vaccines were similarly fraught and yet we managed to make it work and we made it work very quickly for covert. Did we learn anything from that. That could be applied to antibiotics. There were changes in financing operation. Works beat the big investments by the. Us government was eighteen billion dollars but there also were changes in how clinical trials restructured the way in which the fda staff was willing to talk to companies as clinical trials. Were going through. There were guarantees of purchase at the far end through a whole bunch of things that just flattened the various hurdles that would keep a drug from getting to market and that was appropriate right because kovin has been the worst public health challenge in more than one hundred years. The people who develop antibiotics say look resistance is really serious at some point. We are going to face something like this. We should consider this kind of making the landscape easier for new antibiotics as well so that we have them in time when we need them maryn mckenna journalist and senior fellow at the center for the study of human health at emory university. Thank you so much for joining us. Thank you you can hear more of my conversation with maryn mckenna at marketplace dot org. I'm super venice shore with the marketplace morning from apm american public media. Hey jed kim host a million bazillion million brazilian is a podcast for kids in the families that helps dollars make more sense in each episode. We tackle the tricky questions that your kids have about money. Like how is it made. Is there a factory somewhere that makes it. Or what determines the price of pizza and we're back with all new episodes. That's more answers to the questions. Your kids wanna know thoughtful ones. The silly ones and the really hard. To answer one's million zillion. Listen wherever. get your podcasts..